The Cooper Companies (COO) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $0.91 per share when it actually produced earnings of $0.96, delivering a surprise of 5.49%.Over the las ...

Revenue and Growth - Q4 2024 revenue of $1,018.4 million, up 10% YoY, with organic growth of 7%[1] - Fiscal year 2024 revenue of $3.9 billion, up 8% YoY, with organic growth of 8%[1] - Q4 2024 CooperVision (CVI) revenue of $676.4 million, up 9% YoY, with organic growth of 8%[7] - Q4 2024 CooperSurgical (CSI) revenue of $342.0 million, up 12% YoY, with organic growth of 5%[10] - Fiscal 2025 revenue guidance of $4,080 - $4,158 million, with organic growth of 6% to 8%[15] - Net sales for Q4 2024 increased by 10% year-over-year to $1,018.4 million, with organic growth of 7%[57] - CooperVision's net sales grew by 9% year-over-year to $676.4 million, with organic growth of 8%[57] - CooperSurgical's net sales increased by 12% year-over-year to $342.0 million, with organic growth of 5%[57] Earnings and Profitability - Q4 2024 GAAP diluted EPS of $0.58, up 38% YoY, and fiscal 2024 GAAP diluted EPS of $1.96, up 33% YoY[2] - Q4 2024 non-GAAP diluted EPS of $1.04, up 19% YoY, and fiscal 2024 non-GAAP diluted EPS of $3.69, up 15% YoY[2] - Q4 2024 gross margin of 67%, up from 65% in the prior year, driven by price and efficiency gains[4] - Q4 2024 operating margin of 19%, up from 15% in the prior year, driven by SG&A expense leverage and stronger gross margins[4] - Fiscal 2025 non-GAAP diluted EPS guidance of $3.92 - $4.02[15] - GAAP Net Income for the three months ended October 31, 2024, was $117.5 million, compared to $84.5 million in the same period in 2023[27] - Non-GAAP Net Income for the three months ended October 31, 2024, was $208.5 million, compared to $173.2 million in the same period in 2023[27] - Net income for Q4 2024 rose to $117.5 million, up from $84.5 million in Q4 2023[54] - Earnings per share (diluted) for Q4 2024 were $0.58, compared to $0.42 in Q4 2023[54] - Gross profit for Q4 2024 was $677.7 million, up from $606.5 million in Q4 2023[54] Expenses and Charges - Acquisition and integration-related charges for the three months ended October 31, 2024, were $7.2 million, primarily related to the Cook Medical acquisition[28] - Business optimization charges for the three months ended October 31, 2024, included $1.5 million in employee severance costs and $1.0 million related to IT infrastructure changes[34] - The twelve months ended October 31, 2024, included $20.6 million in acquisition and integration-related charges, primarily related to the Cook Medical acquisition[28] - The twelve months ended October 31, 2024, also included $18.3 million in business optimization charges, with $10.6 million related to employee severance costs[34] - The company incurred $4.0 million in charges related to compliance with new EU medical device regulations for the three months ended October 31, 2024[32] - The twelve months ended October 31, 2024, included $12.9 million in other charges, with $5.9 million related to gains and losses on minority interest investments[37] - Research and development expenses increased to $37.7 million in Q4 2024 from $36.7 million in Q4 2023[54] Financial Position - Total assets increased to $12,315.2 million in 2024 from $11,658.9 million in 2023[51] - Long-term debt stood at $2,550.4 million in 2024, slightly up from $2,523.8 million in 2023[51] - Total current assets grew to $1,951.5 million in 2024 from $1,704.9 million in 2023[51] Corporate Developments - The company recorded a deferred tax asset of approximately $2.0 billion in fiscal 2021 due to the transfer of CooperVision intellectual property and goodwill to its UK subsidiary[39] - The company will host an audio webcast to discuss its fourth-quarter results and corporate developments, available on CooperCompanies' website[39]

SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically.Fourth quarter 2024 GAAP diluted earnings per share (EPS) of $0.58, up 38%. Fiscal 2024 GAAP diluted EPS of $1.96, up 33%.Fourth quarter ...

Breaking News: Brenmiller Energy COO Will Present At The Emerging Growth Conference Today At 11:25 AM ESTDecember 04, 2024 8:45 AM EST | Source: Hawk Point Media Group.Miami, Florida--(Newsfile Corp. - December 4, 2024) - Brenmiller Energy Ltd. (NASDAQ: BNRG) COO Nir Brenmiller will present at the Emerging Growth Conference on Wednesday, December 4, 2024, at 11:25 AM EST. The fireside-chat-styled interview provides a forum for Mr. Brenmiller to explain how recent announcements position his com ...

Core Viewpoint - The Cooper Companies, Inc. is expected to report strong fourth-quarter fiscal 2024 results, with anticipated revenue growth and earnings improvement compared to the previous year [1][3][11]. Financial Estimates - The Zacks Consensus Estimate for revenues is projected at $1.03 billion, reflecting a 10.8% increase year-over-year [3]. - The consensus estimate for earnings is set at $1.00 per share, indicating a 15% improvement from the prior-year period [3]. Segment Performance - Cooper Companies operates under two main segments: CooperVision (CVI) and CooperSurgical (CSI), both of which have shown strength in recent quarters [4][10]. - CVI's revenues for Q4 are expected to range from $673 million to $685 million, representing organic growth of 8-10% [7]. - CSI's revenues are projected to be between $342 million and $350 million, indicating organic growth of 6-8% [10]. Growth Drivers - The demand for contact lenses has increased, particularly due to a global shift towards daily contact lenses, with CVI's lens business growing 13% in the Americas and 7% in both EMEA and Asia-Pacific [5]. - New product introductions, such as MyDay Energys and upgraded clariti multifocal, along with a successful back-to-school campaign, have contributed to increased consumption [6]. - CSI has benefited from strong demand for fertility and surgical products, particularly the PARAGARD device, and the company's new cryo management software and FastTrack genomics testing have aided sales [8][9]. Earnings Prediction - The company is predicted to beat earnings estimates, supported by a positive Earnings ESP of +1.25% and a Zacks Rank of 3 [11][12].

Wall Street analysts expect The Cooper Companies (COO) to post quarterly earnings of $1 per share in its upcoming report, which indicates a year-over-year increase of 14.9%. Revenues are expected to be $1.03 billion, up 10.8% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this tim ...

I have been looking for exposure to the fertility industry, but have struggled to find appealing long-term options. I previously covered PGNY , but that company has some issues, displaying weakness recently and lacking global exposure. Looking around for a better wayI'm in the last year of my law PhD on the topic of corporate wrongdoing. My main focus in equity research is following up on companies that have been targeted by activist short sellers. I have found these interesting because:i) they are typicall ...

Group 1 - Canadian Pacific Kansas City (CPKC) will present at the 2024 UBS Global Industrials and Transportation Conference on December 4, 2024, at 9:40 a.m. ET [1] - The presentation will be led by President and CEO Keith Creel and Executive Vice-President and COO Mark Redd [1] - A live audio webcast of the event will be available, along with a replay after the event concludes [1] Group 2 - CPKC is the first and only single-line transnational railway connecting Canada, the United States, and Mexico [2] - The railway spans approximately 20,000 route miles and employs 20,000 railroaders, providing extensive rail service across North America [2] - CPKC offers a range of freight transportation services, logistics solutions, and supply chain expertise to its customers [2]

CALGARY, AB, Nov. 19, 2024 /PRNewswire/ - Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) President and Chief Executive Officer Keith Creel and Executive Vice-President and Chief Operating Officer Mark Redd will address the 2024 UBS Global Industrials and Transportation Conference on Dec. 3, 2024, at 8:50 a.m. ET.CPKC will provide access to the live audio webcast at investor.cpkcr.com. A replay will also be available following the conclusion of the event.About Canadian Pacific Kansas CityWith its g ...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advi ...